<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02586818</url>
  </required_header>
  <id_info>
    <org_study_id>INR_CSP_015_0002_RA</org_study_id>
    <nct_id>NCT02586818</nct_id>
  </id_info>
  <brief_title>Clinical Performance of Investigational InRhythm PT/INR System in a Professional Use Setting</brief_title>
  <official_title>Clinical Performance of the Investigational InRhythm PT/INR System in a Professional Use Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Accriva Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Accriva Diagnostics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate and verify the clinical accuracy of the InRhythm PT/INR&#xD;
      system; a point-of-care, whole blood PT/INR measurement with a reference plasma based PT/INR&#xD;
      using a laboratory reference instrument and reagent (Sysmex/lnnovin) calibrated to the WHO&#xD;
      rTF09 reference standard.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Product was discontinued.&#xD;
  </why_stopped>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Comparison of INR measurements</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Blood Dyscrasia</condition>
  <biospec_descr>
    <textblock>
      Whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The population to be studied consists of subjects who require oral anticoagulant therapy&#xD;
        with VKA in accordance with the approved label indications for VKA administration. Normal&#xD;
        healthy individuals will also be enrolled to collect data to support the low end of the&#xD;
        lnRhythm system detection range.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria - All&#xD;
&#xD;
          -  The subjects must be &gt; 18 years of age.&#xD;
&#xD;
          -  The subjects must be willing and competent to sign an informed consent.&#xD;
&#xD;
          -  The subjects must be able to attend the clinic for one visit to donate one FS blood&#xD;
             sample and one venous blood draw of approximately 10 cc.&#xD;
&#xD;
        Exclusion Criteria - All&#xD;
&#xD;
          -  The subject is unable to donate fingerstick and venous blood samples.&#xD;
&#xD;
          -  The subject has a history of clinically significant bleeding associated with incising&#xD;
             the finger and/or the venipuncture.&#xD;
&#xD;
          -  The subject is enrolled in any other study that involves an investigational drug&#xD;
             and/or device.&#xD;
&#xD;
        Additional Inclusion Criteria - Therapeutic Group&#xD;
&#xD;
          -  The subject must require oral VKA anticoagulant therapy.&#xD;
&#xD;
          -  The patient must have been anticoagulated for at least three months prior to&#xD;
             enrollment.&#xD;
&#xD;
        Additional Exclusion Criteria - Normal Group&#xD;
&#xD;
        - Subjects receiving any form of anticoagulation drugs such as Aspirin or Clopidogrel.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 22, 2015</study_first_submitted>
  <study_first_submitted_qc>October 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2015</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

